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Herpes  simplex  virus  type-1  (HSV-1)  and  -2  (HSV-2)  are  highly  prevalent  global  pathogens  which  com-
monly  cause  recurrent  oral  and  genital  ulcerations.  Less  common  but more  serious  complications  include
meningitis,  encephalitis,  neonatal  infection,  and  keratitis.  HSV-2  infection  is a signiﬁcant  driver  of  the
HIV  epidemic,  increasing  the  risk  of HIV  acquisition  3 fold.  As  current  control  strategies  for genital  HSV-
2  infection,  including  antiviral  therapy  and condom  use,  are  only  partially  effective,  vaccines  will  beaccine
required  to reduce  infection.  Both  preventive  and  therapeutic  vaccines  for HSV-2  are  being  pursued  and
are in  various  stages  of  development.  We  will  provide  an overview  of  efforts  to  develop  HSV-2  vaccines,
including  a discussion  of  the clinical  need  for an HSV  vaccine,  and status  of research  and  development
with  an  emphasis  on recent  insights  from  trials  of  vaccine  candidates  in clinical  testing.  In  addition,  we
will  touch  upon  aspects  of HSV  vaccine  development  relevant  to low  and  middle  income  countries.
 Orga© 2016  World  Health
. About the disease and pathogen
Herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) are respon-
ible for recurrent, painful oral and genital ulcers, and cause
eningitis, encephalitis, neonatal infection, and keratitis. HSV
nfection affects all age groups around the globe. These large DNA
iruses are members of the human herpesvirus family, which also
ncludes the pathogens varicella-zoster virus (VZV), Epstein–Barr
irus, cytomegalovirus, human herpesvirus-6, -7 and -8. HSV-1 and
SV-2 are closely related, sharing >80% identity on the amino acid
evel and both types are capable of infecting the oral or genital skin
r mucosa and cause recurrent ulcerations [1]. The virus infects
pithelial cells at skin or mucosal surfaces, and then infects nerve
ndings, traveling via retrograde transport to the nerve axon, where
t establishes persistent infection in the trigeminal or lumbosacral
 This is an Open Access article published under the CC BY 3.0 IGO license which
ermits unrestricted use, distribution, and reproduction in any medium, provided
he original work is properly cited. In any use of this article, there should be no
uggestion that WHO  endorses any speciﬁc organisation, products or services. The
se of the WHO  logo is not permitted. This notice should be preserved along with
he  article’s original URL.
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264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open accenization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).
ganglia. The virus returns to epithelial surfaces via the axon to
cause oral or genital ulcers or frequent asymptomatic viral shed-
ding. The ability of the virus to be acquired and transmitted in the
absence of symptoms allows it to spread efﬁciently throughout the
population. As most infections are subclinical, disease incidence
and prevalence data underestimate the impact of HSV infection.
Although the clinical manifestations of infection are similar
between HSV-1 and HSV-2, the age groups affected and severity
of infection are inﬂuenced by the infecting virus type, the portal of
entry, host immune status and whether the infection is initial or
recurrent. HSV-1 has been more traditionally associated with oral-
facial infections, although it is now a leading cause of ﬁrst episode
genital herpes and neonatal herpes in high-income countries (HIC)
[2,3], which is likely related to declining HSV-1 acquisition during
childhood in these settings [4]. In LMIC, HSV-1 is rapidly acquired
during childhood, with more than 90% people infected by ado-
lescence [5]. HSV-1 causes oral ulcers of varying severity, from
herpes labialis to gingivostomatitis and pharyngitis. It is the lead-
ing cause of sporadic infectious encephalitis (HSV encephalitis) and
infectious blindness (HSV keratitis) in HIC; the burden of these
complications of HSV-1 infection in LMIC is unknown but is likely
to be high.
Herpes simplex virus type 2 (HSV-2) is a sexually transmit-
ted infection that is the leading cause of genital ulcer disease
(GUD) worldwide [6,7]; HSV-2 also causes neonatal herpes and
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ncreases the risk of acquiring HIV infection. An estimated 417 mil-
ion persons aged 15–49 years old are infected with HSV-2, with
n incidence of 19 million infections per year [8]. HSV-2 is rapidly
cquired among men  and women initiating sexual activity in sett-
ngs with high HSV-2 seroprevalence. For instance, in sub-Saharan
frica, the incidence among women is up to 23 per 100 person
ears and among men  is up to 12 per 100 person years [9]. Neona-
al herpes incidence in HIC is ∼10 cases/100,000 live births [10];
he incidence in LMIC is unknown. Although rare, neonatal herpes
s associated with high morbidity and mortality and no preven-
ion strategies have been identiﬁed. HSV-2 fuels the HIV epidemic
y increasing the risk of HIV acquisition 3-fold [11], likely through
SV-2 associated genital tract inﬂammation [12,13]. In addition,
enital ulcer disease increases the risk of HIV transmission [14]. In
ettings with high HSV-2 prevalence, an estimated 25–50% of HIV
nfections are attributable to HSV-2 [15,16].
Global estimates for the economic burden of HSV infection are
ot available. In the United States, HSV-2 infection is estimated to
ave a total lifetime cost of $540 million US dollars (adjusted to
010 dollars), behind only HIV and HPV in costs among 8 major
TIs [17]. These cost estimates exclude neonatal herpes, which
ad a total hospitalization charge of $35 million in 2006 in the
nited States [10]. These costs also exclude sequelae of HSV-1 infec-
ion and the contribution of HSV-2 infection to HIV susceptibility.
he updated Global Burden of Disease Study (GBD) estimates that
enital HSV resulted in 311,600 years lived with disability (YLD)
n 2013 (95% uncertainty interval 98,300–748,500) due to geni-
al ulcer disease alone [18]. GBD 2013 likely underestimates the
mpact of genital HSV, as these YLD estimates do not include dis-
bility due to neonatal herpes nor the contribution of genital HSV
o HIV susceptibility, which are the most devastating consequences
f infection.
The diagnosis of HSV infection may  be made by demonstrating
he virus is present in oral and genital lesions, using polymerase
hain reaction assays, viral culture or antigen detection. In addition,
ommercially available “type-speciﬁc” serologic assays based on
he glycoprotein surface proteins can differentiate between HSV-
 and HSV-2 infection. Serologic assays for HSV-2 are limited by
ow positive predictive value in low prevalence settings and false
ositive results in some populations [19].
Although HSV clinical recurrences are commonly self-limited,
ome complications can be life-threatening, particularly in those
ith immature or compromised immune systems. Treatment
trategies for genital herpes are limited to the antiviral agents,
cyclovir, valacyclovir, or famciclovir [20]. HSV genital ulcer dis-
ase can be treated by the antiviral agent acyclovir, which is now
ncluded in WHO  guidelines for syndromic management of GUD
21]. While episodic therapy for genital ulcers shortens the dura-
ion of the ulcer by approximately 1 day, daily suppressive therapy
revents most recurrences. Although daily suppressive therapy for
SV-2 infected persons decreases the risk of transmission by ∼50%
n discordant heterosexual partnerships in the US [22], such ther-
py was not effective for prevention of HSV-2 transmission from
IV-1/HSV-2 co-infected adults to HIV-1/HSV-2 seronegative part-
ers in discordant heterosexual African couples [23]. In addition,
uppressive antiviral therapy for HSV does not reduce the risk of
IV-1 acquisition or HIV-1 transmission [24,25]. Condoms have
artial efﬁcacy in preventing acquisition of genital herpes [26].
. Overview of current efforts
.1. Biological feasibility for vaccine developmentThere are no vaccines currently available for HSV infection, but
he pipeline is rich with candidates in various phases of devel-
pment. Vaccines are currently being developed both to prevent4 (2016) 2948–2952 2949
HSV-2 infection (preventive) and to treat HSV-2 infection (ther-
apeutic). While most HSV vaccine research has prioritized HSV-2
rather than HSV-1, HSV-2 vaccines may  also have beneﬁts in pre-
venting or treating HSV-1 infection given the homology between
these viruses.
There are several lines of evidence that an HSV vaccine is feasi-
ble:
1. There is a safe and efﬁcacious vaccine for varicella zoster
virus (VZV), a closely related alpha-herpesvirus. Both a live-
attenuated vaccine for preventive (prevention of varicella
“chicken pox”) and therapeutic (prevention of herpes zoster or
“shingles”) indications have been developed [27]. In addition, a
subunit vaccine with a novel adjuvant was  shown to prevent
herpes zoster with 97% efﬁcacy in a recent Phase III clinical trial
[28].
2. Whether protective genital mucosal immunity could be induced
by an intramuscular (IM) vaccination has been a concerning
unknown for the HSV vaccine ﬁeld. The development of the
human papillomavirus (HPV) vaccine provides ample proof of
concept that an IM vaccine can be highly efﬁcacious against a
mucosal genital viral pathogens [29].
3. The Herpevac trial, which tested a truncated glycoprotein D2
(gD2t) vaccine in >8000 HSV-1/HSV-2 seronegative women
showed 58% vaccine efﬁcacy for prevention of genital HSV-1
disease and 32% efﬁcacy for prevention of HSV-1 infection [30].
The vaccine did not prevent HSV-2 disease or infection. Titers
of antibodies to gD2t were identiﬁed as a correlate of HSV-1
protection, based on increasing vaccine efﬁcacy with increasing
titers of gD2t [31]. Further studies showed that sera of vacci-
nees neutralized HSV-1 3-fold better than HSV-2, suggesting that
vaccine-induced antibodies to gD2 were sufﬁcient to prevent
HSV-1 but not HSV-2 infection. These are the ﬁrst data suggest-
ing that antibody titers are a correlate of anti-HSV-1 immunity
and provide a benchmark for inducing protective immunity.
4. Successful vaccination based eradication campaigns have been
implemented for alphaherpesviruses which infect animals, such
as bovine herpesvirus-1 and suid herpesvirus-1 (pseudorabies
virus) [32,33].
The recent availability of full-length viral sequences from
around the world for both HSV-1 and HSV-2, will allow selection
of vaccine targets that could potentially provide protection against
both pathogens and targets that are not geographically restricted
[34–36]. This combined with increasing knowledge regarding the
role of neutralizing antibodies and T-cell responses in preventing
infection or modulating recurrent disease could help improve the
design of future candidate vaccines.
2.2. General approaches to vaccine development for this disease
for low and middle income country markets
Two  approaches are being pursued for HSV-2 vaccine devel-
opment: preventive vaccines and therapeutic vaccines. Preventive
vaccines would provide protective immunity against genital HSV-
2 infection prior to exposure, with a possible secondary effect
of prevention of HIV infection in high risk populations. The tar-
get population would be adolescent men  and women  prior to the
initiation of sexual activity. Prior studies of preventive HSV vac-
cines have focused on HSV-2 discordant couples or HSV-1/HSV-2
seronegative women  in HIC; these studies have been limited by
low numbers of study endpoints (acquisition of genital herpes dis-
ease), resulting in large sample sizes and prolonged Phase III trials.
Preventive vaccines have not been tested in LMIC. However, given
the disproportionate burden of both HSV-2 and HIV infection in
LMIC, an HSV-2 vaccine must be effective in these populations to
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ave a global impact. HSV vaccines that will be tested in LMIC
ust be designed to have efﬁcacy in both HSV-1 seropositive and
SV-1 seronegative persons, and geographic strain diversity must
e accounted for in vaccine design. In addition, testing of preven-
ive vaccines in LMIC where HSV-2 is rapidly acquired among young
dults will allow for more efﬁcient trials. If a candidate vaccine were
ound to protect against HSV-1 as well as HSV-2 in adolescents in
IC, shifting the timing of vaccination to infancy/childhood with
ossible booster in adolescence could also be considered. Such a
accine may  also prevent HSV-1 related eye and neurologic disease.
hese issues do not have clear consensus in the ﬁeld.
Therapeutic vaccines are being tested in HSV-2 seropositive per-
ons to reduce genital lesions and genital shedding, which may
rovide both personal and public health beneﬁt. The target pop-
lation for these vaccines is persons who already have recurrent
enital HSV-2 infection. Phase I/II studies of 2 candidate therapeu-
ic vaccines have demonstrated antiviral effects, with decreased
ate of shedding and lesions and decreased quantity of virus shed
37]. Mathematical models suggest that there is a genital viral load
hreshold associated with sexual transmission [38]. Therapeutic
accines are being tested in HIC at this time, and there is no con-
ensus regarding prioritization of testing these vaccines in LMIC.
n essential issue that will need to be addressed is the effect of
herapeutic vaccines on genital inﬂammation. A therapeutic HSV-2
accine could reduce genital inﬂammation if viral shedding is con-
ained; alternatively, therapeutic vaccines could result in increased
enital inﬂammation as additional T-cells trafﬁc to the genital tract,
heoretically further increasing the risk of acquiring HIV.
. Technical and regulatory assessment
Preclinical development of HSV vaccines utilizes well-
stablished animal models to screen and test promising candidate
accines. However, HSV is a uniquely human pathogen, and the
ost-virus interactions differ in people, likely accounting for
imited predicted value for efﬁcacy observed in animal models. The
ouse model is convenient due to the availability of many tools to
issect the immune response, but has limitations, including lack of
able 1
evelopment Status of Current Vaccine Candidates.
Candidate name/identiﬁer Pharmaceutical
developer
Platform/antigens 
GEN-003 Genocea Subunit vaccine: gD2/ICP4 with Matr
HerpV Agenus 32 35-mer peptides, complexed with
adjuvant
Codon optimized
polynucleotide vaccine
Admedus DNA vaccine: gD2 codon optimized/u
VCL-HB01/HM01 Vical DNA vaccine: gD2+/−UL46/Vaxfectin
HSV529 Sanoﬁ Replication-defective HSV-2 with de
UL29
gD2/gC2/gE2 Subunit vaccine: gD2/gC2/gE2 
HSV-2 0NLS Live, attenuated replication-compete
deletion of ICP0
HF10 Live, attenuated replication-compete
for UL43, UL49.5, UL55, UL56, LAT
gD2 Live, attenuated HSV-2 deleted in gD
AD472 HSV-2 mutated for g34.5, UL43.5, UL
US11, US12
CJ2-gD2 Non-replicating gD2 dominant neg H
Prime-pull strategy “Prime” with live attenuated HSV-2 f
with topical intravaginal CXCL9/CXC
Inactivated HSV-2 in
MPL/alum
Formalin inactivated HSV-2 
HSV-1 glycoprotein B
lentiviral vector
Lentiviral vector expressing gB1 
gB1s-NISV Intranasal non-ionic surfactant vesic
recombinant HSV-1 gB
D, glycoprotein D; ICP, infected cell protein; HSP, Heat shock protein; UL, unique long; g
onophosphoryl lipid A; gB, glycoprotein B; T, therapeutic; P, preventive.4 (2016) 2948–2952
genital reactivation and high mortality in initial infection [39]. The
guinea pig model appears to mimic human HSV-2 infection better
than the mouse model as spontaneous reactivation in the genital
track occurs [40]. However, promising vaccines in the guinea pig
model have not translated to efﬁcacy in humans. There is often a
long delay in testing vaccine candidates with efﬁcacy in animal
models in clinical trials.
For therapeutic vaccines in early stages of clinical develop-
ment, HSV genital shedding has recently been used as a surrogate
endpoint rather than the more traditional endpoint of recurrence
frequency. Genital shedding has the potential to more precisely
deﬁne the most effective vaccine dose rather than recurrences,
which may  not be recognized by participants [41]. In addition, the
use of a cross-over design in which the effect of the intervention can
be directly measured allows for efﬁcient trial design with a limited
follow-up period and a relatively small number of participants.
4. Status of vaccine R&D activities
Multiple vaccine candidates with diverse platforms have been
studied in the preclinical phase and several are being tested in
clinical trials, with early development supported mainly by aca-
demic institutions, government, and biotech companies. Several
pharmaceutical companies have also been involved with testing
HSV vaccines.
The most widely used product for HSV vaccines in human clini-
cal trials has been glycoprotein subunit vaccines. Glycoprotein D is
expressed on the viral surface and responsible for most neutral-
izing antibody activity and, therefore, is a rationale target [42].
The largest clinical trial of an HSV subunit vaccine, Herpevac,
enrolled HSV-1/HSV-2 seronegative women  and used glycoprotein
D-2 (gD2) with alum/MPL adjuvant [30]. Although the Herpevac
trial did not show efﬁcacy against HSV-2 disease, the ﬁnding that
the vaccine prevented genital HSV-1 disease (vaccine efﬁcacy = 58%,
95% CI 12–80%) is a signiﬁcant advance for the HSV ﬁeld [30]. In
addition, identiﬁcation that the gD2 antibody concentrations cor-
related with protection against HSV-1 infection, provides proof
of concept that protective mucosal immunity can be stimulated
Pre-clinical Phase I Phase II Phase III Refs.
ix M2 adjuvant X (T) [37,51,52]
 HSP, QS-21 X (T) [53]
biquitin-tagged X (T) [54]
 X (T) [55]
letions of UL5 and X (P&T) [56]
X [49]
nt HSV-2 with X [57]
nt HSV-1 mutated X [58]
2 X [44]
55-56, US10, X [59]
SV-2 X [60]
ollowed by “pull”
L10 chemokine
X [48]
X [61]
X [62]
les containing X [63]
C, glycoprotein C; gE, glycoprotein E; US, unique short; TK, thymidine kinase; MPL,
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hrough vaccination [31], although it is not clear whether this is
 mechanistic correlate [43]. Second generation preventive vac-
ines may  need to stimulate higher titers of neutralizing antibody
r induce other immune responses for more complete protection
gainst HSV-1 or HSV-2.
There are several live-attenuated or replication-defective virus
accine candidates in the preclinical phase (Table 1). A replication-
efective HSV-2 vaccine (HSV529) has entered Phase I trials for
oth preventive and therapeutic indications. A live-attenuated
irus deleted in gD2 prevented skin, neural and vaginal disease
n the mouse model, and also is the ﬁrst construct to eliminate
stablishment of latency in the dorsal root ganglia [44]. Concerns
bout recombination with wild type virus and retained pathogenic
otential (especially with respect to central nervous system inva-
ion) have limited the investigations into live-attenuated candidate
roducts [45].
Within the past 2 years, 4 additional candidates have entered
nto Phase I/II trials as therapeutic vaccines. These vaccine can-
idates have novel adjuvants which stimulate T cell immunity.
reliminary results were reported for GEN-003, a gD2/ICP4 protein
ubunit vaccine with Matrix M adjuvant, with ∼50% decline in gen-
tal HSV shedding rate after the therapeutic vaccine series [37]. This
andidate vaccine is currently in a Phase II dose-ranging safety and
fﬁcacy trial. Preliminary results from a Phase II study of HerpV,
 peptide vaccine with 32 peptides linked to heat shock protein
HSP) and QS-21 adjuvant, showed a 15% decrease in viral shed-
ing, which persisted up to 6 months after the initial vaccine series
46]. A DNA vaccine with gD/UL46, adjuvanted with Vaxfectin® has
lso entered Phase I/II trials for a therapeutic indication, with initial
esults expected in mid-2015.
The realization that genital HSV infection induces tissue resi-
ent memory T cells in human genital mucosa has been a recent
dvance in the ﬁeld [47]. Animal studies have demonstrated the
mportance of stimulating tissue resident memory T-cells for pre-
ention of HSV infection in the mouse model using a “prime and
ull” approach, in which a topical chemokine applied to the genital
ucosa after subcutaneous vaccination drew HSV speciﬁc CD8+ T
ells and was associated with decreased clinical disease upon chal-
enge with HSV-2 [48]. While this approach has not entered clinical
rials, it is an innovative and highlights the importance of tissue
esident T cells in the genital tract.
Novel delivery methods of glycoproteins, including lentiviral
ectors expressing glycoprotein B and intranasal delivery, are being
xplored. Glycoprotein candidates with novel platforms are still
eing investigated. For instance, a gD/gC/gE subunit glycoprotein
andidate is promising in mice [49].
. Likelihood for ﬁnancing
As HSV-2 infection greatly enhances the risk of HIV acquisition
nd transmission, it is possible that prevention of HSV-2 infec-
ion with a vaccine would have a substantial impact on reducing
ncident HIV infections, as predicted by modeling studies [50]. In
his case, the vaccine may  be supported in part by the Global Fund
o Fight AIDS, Tuberculosis and Malaria in addition to GAVI. New
lobal estimates for neonatal herpes, which are currently being
ompleted, and better primary data on neonatal herpes incidence
n LMIC will additionally help inform the likelihood of GAVI prior-
tization based on under 5 lives saved in GAVI eligible countries.
lthough neonatal HSV is relatively rare in HIC, there are few
ata regarding incidence in LMIC. This condition has a 60% fatal-
ty rate without treatment and can result in lifelong neurological
eﬁcits, even with successful treatment. Although concerns have
een raised in some settings about providing an STI vaccine to pre-
dolescents, GAVI support for HPV vaccine offers a clear precedent
[
[4 (2016) 2948–2952 2951
for GAVI prioritization of an adolescent vaccine against a sexually
transmitted infection.
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